Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.76 |
| ▸ | ITGA2B | P08514 | 18/20 | 0.76 |
| ▸ | MIF | P14174 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214752 | 1.00 | ITGB3 (0.76) | ITGB3ITGA2BMIF | |
| SCHEMBL7214664 | 1.00 | ITGB3 (0.76) | ITGB3ITGA2BMIF | |
| SCHEMBL7220986 | 0.87 | ITGB3 (0.83) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL24336949 | 0.86 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL344302 | 0.86 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL919675 | 0.84 | ITGB3 (0.95) | ITGB3ITGA2B | |
| SCHEMBL7229682 | 0.84 | ITGB3 (0.74) | ITGB3ITGA2BMIF | |
| SCHEMBL7409072 | 0.84 | ITGB3 (0.73) | ITGB3ITGA2B | |
| SCHEMBL7231799 | 0.83 | ITGB3 (0.72) | ITGB3ITGA2B | |
| SCHEMBL7413714 | 0.83 | ITGB3 (0.80) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624311-B2 | Forming roxifiban | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-09-23 | — | — | US | claimed |
| US-20020160465-A1 | Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester | BRITOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-10-31 | — | — | US | claimed |
| US-6624311-B2 | Forming roxifiban | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6624311-B2 | Forming roxifiban | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020160465-A1 | Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester | BRITOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-10-31 | — | — | US | disclosed |
| US-20020160465-A1 | Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester | BRITOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160465-A1 | Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester | ANPEP, DAO, DNPEP | ITGB3 128/4885ITGA2B 106/4885MIF 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.